|
|
 |
 |
| |
 Printable version |
Future treatments |
Hépato-Gastro. Volume 17, Number 5, 51-60, novembre 2010, mini-revue
|
 Résumé
Texte intégral
|
Author(s) : Jean-Michel Pawlotsky |
Summary : Numerous specific inhibitors of hepatitis C virus (HCV) are currently under development. The most advanced drugs in development to date are protease inhibitors and HCV replication inhibitors. The latter include nucleos(t)ide analogues, non nucleoside inhibitors of HCV RNA dependent-RNA polymerase, NS5A protein inhibitors and cyclophylin inhibitors. Two protease inhibitors, telaprevir and boceprevir, are currently under evaluation in combination with peginterferon-α and ribavirin, in Phase III trials. Triple combination should become soon the standard of care in HCV genotype 1 infected patients. In the next future, oral treatment of chronic hepatitis C may be envisaged, at least in subgroups of patients. |
Keywords : specific inhibitors, protease inhibitors, replication, telaprevir, boceprevir |
|
